Manual or electroacupuncture as an add-on therapy to SSRIs for depression: A randomized controlled trial

Zhao, Bingcong; Li, Zhigang; Wang, Yuanzheng; Ma, Xuehong; Wang, Xiangqun; Wang, Xueqin; Liu, Jianping; Huang, Yong; Li, Liqin; Hu, Xiao-Yang; Jiang, Jinfeng; Qu, Shanshan; Chai, Qianyun; Song, Mengjia; Yang, Xiaojian; Bao, Ting; Fei, Yutong

doi:10.1016/j.jpsychires.2019.04.005

Cited by 44 publications

(50 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…EA has been found to be effective in treating with depression with few side effects in a number of clinical studies, [ 27 – 30 ] but an updated Cochrane review [ 18 ] concluded that there was lack of solid evidence to recommend that EA is a beneficial treatment for depressive patients in many aspects due to poor quality of previous trials, which required further high-quality trials to support the recommendation. Besides, fluoxetine, as a selective serotonin reuptake inhibitor, is a widely used antidepressant.…”

Section: Discussionmentioning

confidence: 99%

Effects of electroacupuncture therapy for depression

Cai

Ma²,

Chen³

et al. 2020

Medicine

View full text Add to dashboard Cite

Introduction: As a major public health problem, depression has a negative impact on individuals and society. The aim of this well-designed trial is to evaluate the efficacy and safety of electroacupuncture (EA) treatment for depression. Methods/Design: A 3-arm parallel, nonblinded, randomized controlled trial will be performed in 4 hospitals (centers). A total of 144 participants will be divided into 3 groups: EA group, manual acupuncture (MA) group, and western medicine group. Participants in EA group and MA group will receive 12 sessions of acupuncture treatment for 4 weeks. Participants allocated to western medicine group will only take 20 mg fluoxetine orally per day for 4 weeks. The primary outcome is Hamilton Depression Scale. Secondary outcomes are Self-Rating Depression Scale, Depression Scale of traditional Chinese medicine (Depression Scale of Traditional Chinese Medicine), brain fMRI and blood biomarkers including neurotransmitters serotonin, dopamine, noradrenaline, inflammatory cytokines inerleukin (IL)-1β, tumor necrosis factor-α, IL-6, and neurotrophin BDNF. All the outcomes will be assessed at baseline, 4 weeks after EA treatment onset and 6-month follow-up. Discussion: The results of this trial will verify the efficacy and safety of EA treatment for depressive patients and provide acupuncturists and clinicians with robust clinical evidence. Trial registration: Chinese Clinical Trial Registry identifier: ChiCTR1900023420. Version 1. Registered on 26 May 2019. http://www.chictr.org.cn/edit.aspx?pid=37621&htm=4

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of electroacupuncture therapy for depression

Cai

Ma²,

Chen³

et al. 2020

Medicine

View full text Add to dashboard Cite

show abstract

“…EA has been found to be effective in treating with depression with few side effects in a number of clinical studies [27][28][29][30] , but an updated Cochrane review [18] concluded that there was lack of solid evidence to recommend that EA is a beneficial treatment for depressive patients in many aspects due to poor quality of previous trials, which required further high quality trials to support the recommendation. Besides, fluoxetine, as a selective serotonin reuptake inhibitor (SSRI), is a widely used antidepressant.…”

Section: Discussionmentioning

confidence: 99%

Effects of electroacupuncture therapy for depression: study protocol for a multi-centered, randomized controlled trial

Cai

Chen

et al. 2019

Preprint

View full text Add to dashboard Cite

Background As a major public health problem, depression has a negative impact on individuals and society. The aim of this well-designed trial is to evaluate the efficacy and safety of electroacupuncture (EA) treatment for depression. Methods/Design A three-arm parallel, non-blinded, randomized controlled trial was performed in four hospitals (centers). 144 participants will be divided into three groups: electroacupuncture (EA) group, hand acupuncture (HA) group and western medicine group. Participants in EA group and HA group received 12 sessions of acupuncture treatment for 4 weeks. Participants allocated to western medicine group will only take 20mg fluoxetine orally per day for 4 weeks. The primary outcome is Hamilton Depression Scale (HAMD). Secondary outcomes are Self-Rating Depression Scale (SDS), Depression Scale of traditional Chinese medicine (Depression Scale of TCM), brain fMRI and blood biomarkers including neurotransmitters 5-HT, DA, NE, inflammatory cytokines IL-1β, TNF-α, IL-6 and neurotrophin BDNF. All the outcomes will be assessed at baseline, 4 weeks after EA treatment onset and 6-month follow-up. Discussion The results of this trial will verify the efficacy and safety of EA treatment for depressive patients and provide acupuncturists and clinicians with robust clinical evidence.

show abstract

“…Secondary outcomes include the rates of depression response and remission at the 8th week (endpoint), where response is defined as a reduction of 50% of the HAMD-17 score and remission as a HAMD-17 score of 7 or less [22]; the rates of pain response at the 8th week, where response is defined as a reduction of 2 points of the BPI-WP [23,24]; alpha in patients with obstructive sleep apnea-hypopnea syndrome with cognitive impairment [25]. The total MoCA score is 30 points, and less than 26 points is considered to indicate cognitive impairment.…”

Section: Secondary Outcomesmentioning

confidence: 99%

Acupuncture for comorbid mild-moderate depression and chronic musculoskeletal pain: study protocol for a randomized controlled trial

Sheng

Liu

Huang

et al. 2021

Trials

View full text Add to dashboard Cite

Background Depression and chronic musculoskeletal pain (CMSP) are the leading causes of years lived with disabling diseases worldwide. Moreover, they often commonly coexist, which makes diagnosis and treatment difficult. A safe and effective treatment is urgently needed. Previous studies have shown that acupuncture is a cost-effective treatment for simple depression or CMSP. However, there is limited evidence that acupuncture is effective for depression comorbid with CMSP. Methods This is a randomized, sham acupuncture-controlled trial with three arms: real acupuncture (RA), sham acupuncture (SA), and healthy control (HC). Forty-eight depression combined CMSP participants and 12 healthy people will be recruited from GDTCM hospital and randomized 2:2:1 to the RA, SA, and HC groups. The patients will receive RA or SA intervention for 8 weeks, and HC will not receive any intervention. Upon completion of the intervention, there will be a 4-week follow-up. The primary outcome measures will be the severity of depression and pain, which will be assessed by the Hamilton Depression Rating Scale (HAMD-17) and Brief Pain Inventory (BPI), respectively. The secondary outcome measures will be cognitive function and quality of life, which will be measured by the Montreal Cognitive Assessment (MoCA), P300, and World Health Organization Quality of Life (WHOQOL-BREF). In addition, the correlation between brain-derived neurotrophic factor (BDNF) and symptoms will also be determined. Discussion The aim of this study is to evaluate the clinical efficacy and underlying mechanism of acupuncture in depression comorbid with CMSP. This study could provide evidence for a convenient and cost-effective means of future prevention and treatment of combined depression and CMSP. Trial registration Chinese Clinical Trial Registry ChiCTR1800014754. Preregistered on 2 February 2018. The study is currently recruiting.

show abstract

Manual or electroacupuncture as an add-on therapy to SSRIs for depression: A randomized controlled trial

Cited by 44 publications

References 33 publications

Effects of electroacupuncture therapy for depression

Effects of electroacupuncture therapy for depression

Effects of electroacupuncture therapy for depression: study protocol for a multi-centered, randomized controlled trial

Acupuncture for comorbid mild-moderate depression and chronic musculoskeletal pain: study protocol for a randomized controlled trial

Contact Info

Product

Resources

About